MacroGenics Inc (NASDAQ:MGNX)’s share price was down 3.7% during mid-day trading on Tuesday . The company traded as low as $27.24 and last traded at $27.38, with a volume of 79,057 shares. The stock had previously closed at $28.43.

A number of equities analysts recently issued reports on MGNX shares. BTIG Research started coverage on shares of MacroGenics in a research note on Thursday, April 7th. They issued a “buy” rating and a $35.00 price target for the company. Morgan Stanley raised their target price on shares of MacroGenics from $20.00 to $21.00 in a research note on Friday, April 8th. Zacks Investment Research raised shares of MacroGenics from a “strong sell” rating to a “hold” rating in a research note on Wednesday, May 4th. Wedbush reaffirmed an “outperform” rating and set a $52.00 target price on shares of MacroGenics in a research note on Wednesday, May 4th. Finally, Leerink Swann reaffirmed an “outperform” rating and set a $47.00 target price on shares of MacroGenics in a research note on Thursday, May 19th. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating to the company. MacroGenics currently has a consensus rating of “Buy” and a consensus price target of $40.25.

The stock’s market cap is $935.48 million. The company’s 50 day moving average price is $26.22 and its 200-day moving average price is $21.32.

MacroGenics (NASDAQ:MGNX) last released its quarterly earnings data on Wednesday, May 4th. The biopharmaceutical company reported ($0.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by $0.21. On average, equities analysts forecast that MacroGenics Inc will post ($2.29) EPS for the current year.

In other MacroGenics news, VP Lynn Cilinski sold 8,922 shares of the business’s stock in a transaction dated Friday, July 1st. The shares were sold at an average price of $27.22, for a total value of $242,856.84. Following the completion of the sale, the vice president now directly owns 10,845 shares of the company’s stock, valued at approximately $295,200.90. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CMO Jon Marc Wigginton sold 5,000 shares of the business’s stock in a transaction dated Friday, July 1st. The shares were sold at an average price of $27.22, for a total transaction of $136,100.00. Following the completion of the sale, the chief marketing officer now directly owns 5,000 shares of the company’s stock, valued at $136,100. The disclosure for this sale can be found here.

A number of large investors recently added to or reduced their stakes in the stock. Pinnacle Associates Ltd. boosted its stake in MacroGenics by 46.5% in the fourth quarter. Pinnacle Associates Ltd. now owns 716,350 shares of the biopharmaceutical company’s stock valued at $22,185,000 after buying an additional 227,260 shares during the period. Jennison Associates LLC boosted its stake in MacroGenics by 0.3% in the fourth quarter. Jennison Associates LLC now owns 267,408 shares of the biopharmaceutical company’s stock valued at $8,282,000 after buying an additional 909 shares during the period. Marshall Wace LLP boosted its stake in MacroGenics by 94.1% in the fourth quarter. Marshall Wace LLP now owns 93,709 shares of the biopharmaceutical company’s stock valued at $2,902,000 after buying an additional 45,422 shares during the period. GAM Holding AG boosted its stake in MacroGenics by 118.3% in the fourth quarter. GAM Holding AG now owns 63,100 shares of the biopharmaceutical company’s stock valued at $1,954,000 after buying an additional 34,200 shares during the period. Finally, California State Teachers Retirement System boosted its stake in MacroGenics by 1.8% in the fourth quarter. California State Teachers Retirement System now owns 58,401 shares of the biopharmaceutical company’s stock valued at $1,809,000 after buying an additional 1,038 shares during the period.

MacroGenics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company operates through developing monoclonal antibody-based therapeutics for cancer, autoimmune and infectious diseases segment.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.